Vidt Donald G
Department of Nephrology and Hypertension, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Am J Cardiol. 2006 Jan 16;97(2A):20A-27A. doi: 10.1016/j.amjcard.2005.11.012. Epub 2005 Dec 1.
Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-CRP) levels have been shown to predict all-cause and cardiovascular mortality in patients dependent on dialysis and to predict worsening renal function in subjects without overt renal disease. Levels of hs-CRP are also predictive of hypertension, a major risk factor for renal disease, across all levels of blood pressure in subjects without initial hypertension. Many of the treatments used in patients with renal disease exert anti-inflammatory activities that constitute or contribute to their therapeutic effects. A number of studies have indicated that statin therapy exerts a renoprotective effect that is possibly mediated by anti-inflammatory activities.
炎症是肾脏疾病主要可改变的风险因素之一。高敏C反应蛋白(hs-CRP)水平升高已被证明可预测依赖透析患者的全因死亡率和心血管死亡率,并可预测无明显肾脏疾病患者的肾功能恶化。在无初始高血压的受试者中,无论血压处于何种水平,hs-CRP水平也可预测高血压,而高血压是肾脏疾病的主要风险因素。肾脏疾病患者使用的许多治疗方法具有抗炎活性,这些活性构成或有助于其治疗效果。多项研究表明,他汀类药物治疗具有肾脏保护作用,这可能是由抗炎活性介导的。